Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience. The company's products include Opdivo for various anti-cancer indicat…
What to know about BMY
Bristol-Myers Squibb Company is a large Healthcare company with a solid overall financial profile. It scores well on risk and size, but growth is worth keeping an eye on.
Should you consider BMY?
Based on 31 financial metrics and sector comparison. Not financial advice.
-
Bristol-Myers Squibb Company is a large-cap Healthcare company with a solid overall financial profile — it ranks in the top quarter of its Healthcare peers (6 of 59).
-
Profit margins are a clear strength, though the balance sheet warrants a closer look — make sure the debt levels are manageable.
-
Valuation is in the middle of the pack — neither obviously cheap nor stretched.
-
Growth has been slower than most peers. That's not necessarily a dealbreaker, but it means the investment case rests more on current earnings than future expansion.
-
There is a small dividend (0.05%), but income-focused investors will likely find better yields elsewhere in the market.
-
Risk is relatively low — the stock tends to be less volatile than the broader market, which typically means a smoother ride during uncertain periods.
-
On balance the positives outweigh the concerns — worth a closer look if Healthcare fits your investment goals.
At a glance
How it scores
We look at 31 different financial metrics and group them into categories. Here's how BMY compares to the other S&P 500 stocks.
Dive deeper — all 31 metrics 9 categories · valuation, growth, health, dividends & more Show all Hide
Valuation
Is the stock cheap or expensive relative to its earnings, sales, and assets? Lower multiples often mean better value.
| Metric | Value | vs S&P 500 |
|---|---|---|
| P/E Ratio (Trailing) | 15.13 | Top 25% |
| Forward P/E | 8.76 | Top 25% |
| PEG Ratio | 177.24 | Below avg |
| Price to Sales | 2.27 | Above avg |
| Price to Book | 5.49 | Average |
| EV/EBITDA | 7.91 | Top 25% |
| Earnings Yield | 6.61% | Top 25% |
Profitability
How efficiently does the company turn revenue into profit? Higher margins mean more money kept from each dollar earned.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Gross Margin | 71.98% | Top 25% |
| Operating Margin | 33.04% | Top 25% |
| Net Profit Margin | 15.01% | Above avg |
| Return on Equity | 38.73% | Top 25% |
| Return on Invested Capital | 10.69% | Top 25% |
Growth
How fast is the business expanding? Strong growth in revenue and earnings signals increasing market demand.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Revenue Growth (YoY) | 2.60% | Below avg |
| Revenue Growth (3Y CAGR) | 1.45% | Average |
| EPS Growth (YoY) | 9.20% | Average |
| Free Cash Flow Growth | -7.87% | Average |
Health
Can the company cover its debts and obligations? A healthy balance sheet reduces the risk of financial trouble.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Current Ratio | 1.42 | Above avg |
| Debt to Equity | 2.31 | Below avg |
| Interest Coverage | 5.93 | Average |
| Altman Z-Score | 2.21 | Average |
Dividends
Does the company pay shareholders, and is that payment growing and sustainable?
| Metric | Value | vs S&P 500 |
|---|---|---|
| Dividend Yield | 4.51% | Top 25% |
| Payout Ratio | 70.03% | Below avg |
| Dividend Growth (5Y) | -3.04% | Top 25% |
Cash Flow
Is real cash flowing into the business — not just accounting profits? Strong cash flow funds growth and dividends.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Free Cash Flow Yield | 10.80% | Top 25% |
| OCF to Sales | 27.44% | Above avg |
Risk
How volatile is the stock compared to the broader market? Lower beta and volatility mean a smoother ride.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Beta (1-Year) | 0.24 | Top 25% |
| Volatility (30-Day) | 25.69% | Above avg |
Sentiment
What do analysts and short-sellers think? High analyst ratings and low short interest signal broad confidence.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Short % of Float | 1.89% | Top 25% |
| Avg. Analyst Rating | — | N/A |
| Target Upside % | 16.81% | Above avg |
Size
How large is the company by market value? Size affects stability, growth potential, and index inclusion.
| Metric | Value | vs S&P 500 |
|---|---|---|
| Market Capitalization | 110.27B | Top 25% |
How does BMY compare to…?
Pick another stock and see them side by side in seconds.
You might also look at
Companies in a similar position to BMY — based on their financial profile.